KW-0761
Phase 3Biologic
Kyowa Kirin Co., Ltd.KW-0761 is one of 81 biologic programs targeting Lymphoma. It is currently in Phase 3.
3
Indications
11
Total Trials
0
Active Trials
80
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
1774 competitors in Lymphoma
#DrugCompanyPhaseTrials
1KW-0761
Kyowa Kirin Co., Ltd.Phase 3
Blenoxane
SSequus Pharmaceuticals
Preclinical
Oncaspar
SServier
Preclinical
Tafasitamab
IncytePreclinical
Solu-Medrol
MMassachusetts Eye and Ear Infirmary
Preclinical
PEG-Intron
Merck & Co.Preclinical
Stem Cells
KKang Stem Biotech Co., Ltd.
Preclinical
R-CHOP
IIncyte Biosciences Japan GK
Preclinical
PD-1 Monoclonal Antibody
SSichuan Baili Pharmaceutical Co., Ltd.
Preclinical
Immune Checkpoint Inhibitor
IImmuneSensor Therapeutics Inc.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Lymphoma3 trials
Leukemia2 trials
Randomized1 trial
3 more indications
Patients With Advanced Solid Tumors1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for KW-0761. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 3[1]
- Company